en 40094094 <p style="text-align:justify"><span style="font-size:11pt"><strong><span style="font-size:10.0pt">Background:</span></strong><span style="font-size:10.0pt"> The utilization of biomarkers is a way to assess the efficacy of recently created anticancer drugs. MiRNAs, telomerase, and Bcl-2 are extensively utilized as biomarkers for this purpose. This study aims to evaluate the comparison of the newly synthesized platinum compounds such as Platinum Azidothymidine (Pt-AZT) with Platinum Levetiracetam (Pt-Lev) on HepG2 cancer cell lines <em>via</em> the biomarkers. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><strong><span style="font-size:10.0pt">Methods:</span></strong><span style="font-size:10.0pt"> In this study, cells were divided into four groups: Group A (HDF cells) were the normal negative control group, group B were HepG2 untreated cancer cells, and groups C and D were treated cancer cells with Pt-AZT and Pt-Lev, respectively. After evaluating the LC₅₀ for the drugs by MTT test, the relative gene expression of the biomarkers was determined by qPCR.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><strong><span style="font-size:10.0pt">Results:</span></strong><span style="font-size:10.0pt"> The results showed a significant decrease for antiapoptotic genes including miRNA-21 (5.1&plusmn;0.014), telomerase (0.56&plusmn;0.48), Bcl-2 (0.41&plusmn;0.276) in group D, whereas in group C was more than group D for miRNA-21 (6.0&plusmn;0.141), telomerase (3.49&plusmn;0.231), Bcl-2 (4.93&plusmn;0.276) also there was a significant increase in miRNA-122 (33.97&plusmn;0.04) in group D, whereas in group C was (28.36&plusmn;0.007) and so lower than group D. Most of the investigated groups showed a significant difference (p&lt;0.05). In addition, there were widespread apoptotic regions in Pt-Lev treatment compared to Pt-AZT. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><strong><span style="font-size:10.0pt">Conclusion:</span></strong> <span style="font-size:10.0pt">The advantages of using Pt-Lev were more powerful anticancer effects on biomarkers through inhibition of antiapoptotic and stimulation proapoptotic factors and also lower side effects and lower drug resistance than Pt-AZT; therefore, it can be considered a more effective anti-cancer therapy.</span></span></p> Bcl-2, Levetiracetam, miRNAs, Telomerase, Zidovudine 24 30 https://www.ajmb.org/En/Article.aspx?id=60599 https://www.ajmb.org/PDF/En/FullText/60599.pdf AbdolrezaSabokrouh793NasimGhaffariDepartment of Biochemistry and Biophysics, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran92268ZahraKarimi Tafreshi Department of Biochemistry and Biophysics, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran92269FreshtehAtabiDepartment of Biochemistry and Biophysics, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran92270ZohrehSharifiBlood Transfusion Research Center, High institute for Research and Education in Transfusion Medicine, Tehran, Iran640Seyyed KhalilShokouhi Mostafavi Department of Microbiology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran92324